Clinical Trial Update: Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Poly-ICLC in recurrent or progressive anaplastic glioma has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Glioma
• Brain and Central Nervous System Tumors

Drugs mentioned

• Poly-ICLC (poly-ICLC)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED | Results posted: 2018-08-21